| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H21N3O3S |
| Molecular Weight | 359.443 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(OC2=CC(C)=C(C#N)C(C)=C2)C(=NN1CS(C)(=O)=O)C3CC3
InChI
InChIKey=QSFGZNVRVZHUGV-UHFFFAOYSA-N
InChI=1S/C18H21N3O3S/c1-11-7-15(8-12(2)16(11)9-19)24-18-13(3)21(10-25(4,22)23)20-17(18)14-5-6-14/h7-8,14H,5-6,10H2,1-4H3
| Molecular Formula | C18H21N3O3S |
| Molecular Weight | 359.443 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
PF-02413873 is a selective nonsteroidal progesterone receptor (PR) antagonist. PF-02413873 is turned over by recombinant human P450s, with CYP3A4 displaying the highest turnover of those enzymes tested. PF-02413873 possessed low oral clearance in human with a pharmacokinetic profile consistent with a once-daily dosing schedule. The pharmacological mode of action of PF-02413873 seems to differ from the founding member of the class of steroidal PR antagonists RU-486. Exposure-effect data from studies in the cynomolgus macaque, however, demonstrated that PF-02413873 reduced endometrial functionalis thickness to a comparable degree to RU-486 and this effect was accompanied by a decrease in proliferation rate for both RU-486 and high-dose PF-02413873. PF-02413873blocked the follicular phase increase in endometrial thickness, the midcycle luteinizing hormone surge, and elevation in estradiol in a dose-dependent fashion compared with placebo. PF-02413873 had been in phase I clinical trial for the treatment of endometriosis. However, this development was discontinued.
